Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Top Cited Papers
- 5 November 2020
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 383 (19), 1827-1837
- https://doi.org/10.1056/nejmoa2015301
Abstract
Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19).Funding Information
- Gilead Sciences
This publication has 17 references indexed in Scilit:
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaNew England Journal of Medicine, 2020
- Covid-19 — Navigating the UnchartedNew England Journal of Medicine, 2020
- Liver injury in COVID-19: management and challengesThe Lancet Gastroenterology & Hepatology, 2020
- Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infectionProceedings of the National Academy of Sciences, 2020
- Ionic liquid-supported magnetite nanoparticles as electrode modifier materials for estrogens sensingScientific Reports, 2020
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoVNature Communications, 2020
- A Randomized, Controlled Trial of Ebola Virus Disease TherapeuticsNew England Journal of Medicine, 2019
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronavirusesScience Translational Medicine, 2017
- Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeysNature, 2016